Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, July 29, 2026

Snapshot: Jul 29, 2026 · 6:00 PM 100 stocks analyzed

Strong Down Day

Wed, Jul 29, 2026 Broad Selloff High

Tech and broad-based carnage drove the S&P 500 down 2.4% and NASDAQ down 4.9% as fear spiked 10.5%, with high dispersion offsetting isolated earnings winners.

60% NASDAQ-led broad selloff with tech bearing the brunt—NASDAQ -4.86%, S&P -2.44%, Russell 2000 -1.81%—as VIX jumped 10.5% signaling renewed risk-off after recent calm, despite a handful of strong earnings beats.
25% Extreme single-stock dispersion dominated the session: 50 gainers averaged +24.3% (led by DCX +77.7%, NUWE +75%, GSUN +73.2%) while 50 losers averaged -28.2% (YYAI -68%, BIOT -56.9%, ZONE -55.2%), with Technology suffering most on the downside at 26% of losers.
15% Earnings-driven winners proved resilient pockets in a hostile tape: HURN +40.7%, MANH +21.2%, EXLS +18.2%, BLKB +17.9%, and CBZ +17.6% on strong results and guidance, while guidance cuts hammered Parsons -35%, Teladoc -22.8%, and Lennox -20.9%.

5 names returned after long absences DCX · 3-day gainers streak YYAI · 3-day losers streak HURN — first appearance GWAV — first appearance

Market Regime

Wed, Jul 29, 2026 Stress conf: medium macro · prototype

-47

Headwind −100 … +100 · + tailwind / − headwind

VIX20.7 p97 Drawdown-3.9% Held1d · nascent SinceJul 29

Top drivers: VIX percentile ▼ VIX 5d momentum ▼ S&P vs 20d avg ▼

processId: history-market-regime

Market Indexes

Wed, Jul 29, 2026 13

S&P 500

7,316.15

−182.81

-2.44%

Dow Jones

51,594.14

−624.44

-1.20%

NASDAQ Composite

24,442.94

−1,247.96

-4.86%

NASDAQ 100

27,192.31

−1,805.79

-6.23%

DJ US Total Market

72,500.65

−1,757.96

-2.37%

Russell 1000

3,986.79

−94.34

-2.31%

S&P MidCap 400

3,734.24

−48.79

-1.29%

Russell 2000

2,906.31

−53.63

-1.81%

Russell 2500

1,243.37

−19.90

-1.58%

Russell 3000

4,165.04

−97.64

-2.29%

Nasdaq Financial-100

7,412.09

−89.96

-1.20%

NIFTY 50

24,250.20

+380.60

+1.59%

VIX

20.66

+1.96

+10.48%

Biggest Gainers

Wed, Jul 29, 2026 50

DCX

Chijet Motor Company, Inc.Consumer Cyclical

$1.12+$0.57

+77.7%

NASDAQ · Mkt cap $322 M

No news headlines were published in the last 48 hours for Chijet Motor Company, so the 77.67% spike cannot be attributed to identifiable company-specific events disclosed to the market.

The complete absence of recent news headlines makes it impossible to pin down a specific catalyst for DCX's dramatic 77.67% gain. For a micro-cap or penny-stock like Chijet Motor (trading at $1.12), price spikes without concurrent news disclosure typically reflect one or more of the following mechanisms: a technical rebound from an oversold condition, retail momentum or social media-driven trading activity, short covering if the stock had significant short interest, delayed disclosure of material information not yet picked up by major news aggregators, or pure speculative trading in a thinly-traded security. Without access to intraday volume data, short interest levels, or insider transaction filings, we cannot distinguish between these scenarios. The company operates in the automotive sector, which can be sentiment-sensitive to EV trends and manufacturing updates, but no specific catalyst is evident from available sources.

NUWE

Nuwellis, Inc.Healthcare

$1.93+$1.44

+75.0%

NASDAQ · Mkt cap $3.7 M

Nuwellis announced first Aquadex SmartFlow installations in Wisconsin's pediatric critical care market, expanding its pediatric ultrafiltration platform footprint and likely driving investor confidence in growth trajectory.

The company disclosed geographic expansion into Wisconsin for its pediatric ultrafiltration technology on July 28, positioning this as evidence of continued market penetration in the pediatric critical care segment. The headline emphasizes this as part of "continued growth" of the pediatric platform, suggesting management views this market as strategically important. For a micro-cap medical device company trading near $1.93, market entry announcements and customer installations can carry outsized weight because they demonstrate commercial traction and reduce execution risk. The 75 percent single-day jump is substantial but not unusual for small-cap medtech stocks responding to positive pipeline or commercialization progress. Without earnings data, guidance changes, or regulatory approvals mentioned in the available headlines, the move appears anchored to the Wisconsin installation announcement as a sign of operational momentum rather than a major financial event.

GSUN

Golden Sun Education Group LimitedConsumer Defensive

$0.32+$0.14

+73.2%

NASDAQ · Mkt cap $3.5 M

No news headlines were available in the last 48 hours, so the 73% jump cannot be directly attributed to a reported event. The move likely reflects either a short-squeeze, technical rebound, or untracked corporate announcement.

Golden Sun Education Group experienced a dramatic 73% single-day gain with no corresponding news in Yahoo Finance's RSS feed over the past two days. This disconnect between price action and available headlines suggests either that the catalyst exists but was not picked up by major financial news aggregators, or that the move is driven by technical factors rather than fundamental news. Penny stocks and small-cap education companies are particularly susceptible to short squeezes when heavily shorted positions unwind, especially if trading volume spikes. Alternatively, the company may have issued a press release through its own channels that has not yet reached mainstream financial media. Without access to company filings, social media, or direct press releases, the specific cause remains unclear, though these are the most probable categories for a move of this magnitude in a micro-cap stock.

GCTK

GlucoTrack, Inc.Healthcare

$0.29+$0.17

+55.6%

NASDAQ · Mkt cap $3.7 M

Glucotrack's subsidiary Lōkahi Therapeutics announced progress on its LT-100 drug development strategy toward single-injection administration on July 29, likely driving the 55.59% gain in GCTK stock.

The headline from July 29 at 21:30 UTC reveals that Lōkahi Therapeutics, a wholly owned subsidiary of Glucotrack, announced advancement in the development strategy for LT-100 focused on evaluation toward single-injection administration. This is a clinical or development milestone for what appears to be a therapeutic candidate. For small-cap biotech and drug development companies like GCTK trading at $0.29, positive clinical progress or development pathway announcements can trigger sharp single-day rallies, especially if the news represents a meaningful de-risking of the program or suggests improved manufacturability or patient convenience. The timing of the announcement matching the trading date strongly suggests this is the direct cause of the move. The stock's ranking as the fourth-biggest gainer on the day further supports that this was a market-moving event for the equity.

AGRZ

Agroz Inc.Consumer Defensive

$0.34+$0.10

+46.1%

NASDAQ · Mkt cap $6.9 M

No news headlines were found in the last 48 hours to explain AGRZ's 46% gain, so the cause cannot be definitively determined from available sources. The move may reflect technical trading, delayed news, or market speculation in this low-priced stock.

Yahoo Finance returned zero headlines for AGRZ in the 48 hours before this +46% jump, which limits analysis to structural inference. AGRZ is a sub-$1 stock trading on NASDAQ, a category where price movements can be amplified by technical factors, low liquidity, and retail speculation. Without confirmed news, this jump could reflect several scenarios: a delayed market reaction to an announcement not yet indexed by the RSS feed, short covering in a thinly traded name, or momentum-driven buying following a technical break. Alternatively, this could be driven by an off-exchange or private announcement not yet reflected in major news feeds. The absence of corroborating headlines is notable and makes fundamental attribution difficult.

SPRC

SciSparc Ltd.Healthcare

$8.54+$2.33

+43.1%

NASDAQ · Mkt cap $3.9 M

SciSparc jumped 43% on July 29 following news that its subsidiary NeuroThera Labs completed internal validation of a quantum-enabled clinical data analytics platform built on an S&P 500 company's infrastructure, a development the market interpreted as material progress in healthcare technology co…

The twin press releases on July 29 announced that NeuroThera, a SciSparc subsidiary, has validated a proprietary quantum computing workflow for clinical trial data analysis. The headlines emphasize that this platform operates on an S&P 500 company's infrastructure, suggesting a partnership or integration with a major established player. The market appears to have reacted positively to both the validation milestone itself and the implicit credibility boost from association with a large-cap partner. This is typical for clinical-stage biotech and healthcare tech plays where proof-of-concept announcements and platform validations can trigger revaluation. However, the headlines do not specify revenue, customer commitments, timelines to commercialization, or the identity of the S&P 500 partner, so the market reaction may be driven partly by optimism about partnerships and potential rather than concrete near-term catalysts.

HURN

Huron Consulting Group IncIndustrials

$169.96+$49.19

+40.7%

NASDAQ · Mkt cap $2.5 B

Huron reported record Q2 2026 revenue with double-digit organic growth, beat both earnings and revenue estimates, and raised full-year 2026 guidance, driving a 40.73% stock surge on July 28-29.

The headlines establish that Huron announced Q2 results on July 28 that substantially exceeded Wall Street expectations. The company reported record revenue before reimbursable expenses, delivered an earnings surprise of +15.49% and revenue surprise of +4.11%, and cited strong double-digit organic growth across its three operating segments driven by digital services and managed healthcare tied to AI initiatives. Critically, management also increased full-year 2026 guidance, which typically signals confidence in sustained momentum. This combination of beat, record performance, growth acceleration, and raised guidance is a classic catalyst for large equity appreciation, particularly for a professional services firm where forward earnings visibility matters heavily. The board appointment on July 27 appears ancillary to the earnings-driven move.

GWAV

Greenwave Technology Solutions, Inc.Industrials

$3.04+$0.91

+36.5%

NASDAQ · Mkt cap $2.9 M

No news headlines were found in the last 48 hours, so the 36.55% gain likely reflects either a delayed market reaction to an earlier announcement, technical buying, short covering, or an unindexed rumor or corporate development that hasn't yet reached major news feeds.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for GWAV's strong one-day move. Greenwave Technology Solutions is a smaller-cap NASDAQ stock, and such companies can experience sharp swings from several sources: a delayed market digestion of older news, short-squeeze activity if the stock has significant short interest, technical breakouts above resistance levels, sector-wide momentum in technology, or unconfirmed corporate developments (earnings release timing, partnership announcement, or management changes) that have not yet propagated to major news aggregators. Without a dated headline or earnings calendar entry visible, we cannot distinguish between these possibilities. The stock's rank as the eighth biggest gainer suggests broad market attention, but that alone does not establish causation.

GENVR

Gen Digital Inc. Contingent Value Rights

$1.82+$0.54

+35.3%

NASDAQ

The 35% jump in GENVR likely reflects market reaction to Gen Digital's Norton brand releasing consumer research highlighting emerging online safety risks for children, potentially signaling renewed corporate focus on cybersecurity products targeting families.

The only headline provided is a Norton (Gen Digital brand) study on digital parenting risks released on July 28, which preceded the price surge on July 29. While the study itself is not a direct business catalyst like earnings or guidance, it represents visible corporate activity and messaging around a core market segment. GENVR is a contingent value right tied to Gen Digital's acquisition, and such instruments can be volatile and respond to sentiment shifts about parent company prospects. The study's emphasis on parental concern about online safety could be interpreted as signaling renewed commercial opportunity in consumer cybersecurity. However, the headline provides no information about product launches, revenue impact, or forward guidance. It is also possible the move reflects other factors entirely: CVR instruments trade on speculation about deal outcomes, tax events, or technical/short-squeeze dynamics unrelated to this specific news.

SBXD.WT

SilverBox Corp IV WT

$0.16+$0.04

+33.7%

Skycorp Solar Group Limited Ordinary SharesEnergy

$10.59+$2.63

+29.0%

NASDAQ · Mkt cap $5.4 M

No news headlines were found in the last 48 hours, so the 29% gain likely reflects a delayed market reaction to a prior announcement, technical buying, or sector momentum in solar stocks.

The absence of recent news makes direct attribution impossible. A 29% single-day jump for a solar company could stem from several plausible sources: a significant earnings beat or guidance raise announced more than 48 hours ago that is only now being fully priced in, a major contract win or partnership, positive regulatory or subsidy news affecting the solar sector broadly, short covering if the stock had been heavily shorted, or general momentum in clean energy equities. Skycorp Solar Group's position as an 11th-largest daily gainer suggests sector-wide strength may be playing a role. Without current headlines, however, we cannot identify the specific catalyst. It is also possible the move reflects accumulated positive sentiment from older news that triggered buying interest today.

MPLT

MapLight Therapeutics, Inc.Healthcare

$15.01+$2.99

+24.2%

NASDAQ · Mkt cap $525 M

MapLight shares rebounded 24% on July 29 after a severe 73% crash on July 27, likely driven by CEO commentary defending the trial data as competitive despite the once-daily dose missing its primary endpoint.

MapLight's stock crashed 73% on July 27 when the company disclosed that its Phase II ZEPHYR trial of ML-007C-MA met the primary endpoint for the twice-daily dosing regimen but failed the once-daily dose endpoint. This was a significant disappointment because once-daily dosing would be more commercially attractive. The subsequent 24% rebound on July 29 follows CEO Christopher Kroeger's public defense of the drug candidate, arguing the "totality of data" still makes the therapy competitive in schizophrenia treatment. This suggests investors may have initially overreacted to the negative headline, and the CEO's on-the-record advocacy provided a narrative rationale for repositioning. The stock remains down substantially from pre-announcement levels, indicating the market has permanently repriced the company's prospects given the dosing failure, but intra-week volatility appears driven by sentiment swings around trial interpretation rather than new clinical facts.

LVWR

Livewire Group IncConsumer Cyclical

$2.53+$0.47

+24.1%

NYSE · Mkt cap $254 M

LiveWire received an NYSE listing compliance notice on July 23 related to share price requirements, and today's 24% gain likely reflects either a relief bounce after clarity on the violation or investor repositioning around the delisting risk.

The headline confirms that LiveWire received a deficiency letter from the NYSE on July 23, 2026, regarding a trading share price listing rule non-compliance. The exact details of the violation are not provided in the snippet, but NYSE deficiency letters typically relate to sustained price levels below minimum thresholds (often $1.00 per share for most tiers). The stock closed at $2.53 today, well above typical minimum thresholds, which suggests either the price had recovered by July 29 or the market is interpreting the notice as less severe than feared. A 24% single-day gain following a compliance notice is unusual and could reflect: (1) market relief that the company acknowledged the issue and will cure it, (2) a short squeeze or technical reversal if the stock had been heavily shorted on delisting fears, or (3) investor confidence in a previously announced remedy or restructuring. Without the full deficiency letter details or any management commentary, the exact mechanism remains unclear.

CLW

Clearwater Paper CorpBasic Materials

$21.59+$4.15

+23.8%

NYSE · Mkt cap $351 M

Clearwater Paper surged 23.77% following Q2 2026 earnings release on July 28–29, likely driven by market relief that losses and challenges were not worse than feared, combined with management's articulated focus on debt reduction and cost-saving measures that signal a credible path forward.

Clearwater Paper reported a Q2 net loss of $21 million ($1.33 per diluted share) on July 28, reflecting pricing pressures and a major maintenance outage that depressed results. On its face, a loss-reporting day should pressure the stock; however, the earnings call headlines emphasize management's strategic response: debt reduction, new product launches, and cost-saving initiatives. The market appears to have interpreted these forward-looking measures as evidence of operational discipline and recovery potential despite near-term headwinds. The company also reported higher shipment volumes, a positive operational signal masked by temporary pricing and maintenance disruptions. The 24% single-day gain suggests investors repriced the stock from distressed expectations to a view that management has a credible playbook to navigate these challenges, rather than a fundamental collapse of the business.

MANH

Manhattan Associates IncTechnology

$204.31+$35.79

+21.2%

NASDAQ · Mkt cap $12 B

Manhattan Associates beat Q2 earnings and revenue estimates on July 28–29, with cloud revenue surging 26% and record bookings driving full-year guidance higher, sparking the 21% rally.

The earnings release on July 28 evening established three bullish catalysts: a 6.11% earnings surprise, a 3.60% revenue beat to $297.8 million (up 9.3% year-over-year), and notably a 26% acceleration in cloud revenue. The company also reported three consecutive quarters of record bookings and raised 2026 guidance. Additional headlines on July 29 highlighted the launch of Sightline, a new AI-driven supply chain planning tool, and emphasized record growth in remaining performance obligations. For a software and cloud services company, this combination of topline and profitability beats coupled with robust forward guidance and strong recurring revenue signals (bookings, remaining performance obligations) typically justifies significant upside revaluation. The market appears to be repricing MANH based on accelerating cloud monetization and AI product innovation in a sector where those metrics drive high multiples.

MWYN

Marwynn Holdings, Inc. Common stockConsumer Cyclical

$0.64+$0.11

+21.2%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours for MWYN, so the 21% gain cannot be attributed to a disclosed catalyst; the move likely reflects technical trading, delayed news dissemination, or unconfirmed rumors in a low-liquidity micro-cap stock.

The absence of any news coverage in the Yahoo Finance RSS feed over the past two days makes it impossible to tie this significant 21% gain to a specific corporate event or announcement. For a micro-cap stock trading at $0.64, price movements of this magnitude are often driven by factors other than fundamental news: thin trading volume can amplify intraday momentum, retail interest in penny stocks can cluster around technical levels or social media discussion, or delayed news from obscure channels may not appear in major RSS feeds immediately. Additionally, very small-cap stocks are more susceptible to rumor-driven rallies, short squeezes, or option expiration mechanics. Without headlines or structural context about MWYN's business, capital structure, or shareholder dynamics, only a generic explanation is possible.

PHOE

PHOENIX ASIA HOLDINGS LIMITEDIndustrials

$21.00+$3.66

+21.1%

NASDAQ · Mkt cap $526 M

No news headlines were found in the last 48 hours, so the cause of PHOE's 21.11% jump cannot be directly attributed to a recent announcement or event; the move likely reflects technical factors, delayed news pickup, or market sentiment shifts.

Yahoo Finance returned no headlines for Phoenix Asia Holdings in the 48 hours preceding this snapshot, making it impossible to ground the move in a specific corporate event or market development. For a stock gaining 21% in a single day without visible news coverage, the catalyst is typically one of several categories: a delayed or under-reported company announcement (earnings, guidance, partnership), technical momentum (short covering, algorithmic buying following a prior catalyst), retail sentiment shifts or social media activity, sector rotation into Asian equities or the relevant industry vertical, or in less frequent cases, an unverified rumor or data error. Without access to real-time trading activity, premarket filings, or out-of-news-feed disclosures, attribution remains speculative. The rank as the 17th biggest gainer suggests this was a material but not exceptional market event for NASDAQ that day.

HUHU

HUHUTECH INTERNATIONAL GROUP INCIndustrials

$6.52+$1.11

+20.4%

NASDAQ · Mkt cap $127 M

No news headlines were found in the last 48 hours to explain HUHUTECH's 20.43% jump, so the catalyst remains unclear and could range from delayed disclosure, technical factors, or broader market sentiment shifts.

Despite a significant 20.43% single-day gain ranking HUHUTECH among the top 18 gainers on NASDAQ, no recent news articles or corporate announcements appear in the available news feed. This absence of headline coverage does not rule out a real catalyst—earnings results, clinical trial data, partnership announcements, or regulatory updates may have been released but not yet picked up by the RSS feed, or they may be available through non-RSS channels or the company's own IR website. Alternatively, the move could reflect technical buying pressure, short covering, or retail attention to a micro-cap stock with naturally volatile trading dynamics. Without verified news or structural insight into this specific company, attribution remains speculative.

BXBL

BOXABL, Inc.Consumer Cyclical

$4.98+$0.81

+20.3%

NASDAQ · Mkt cap $1.6 B

No news headlines were found in the last 48 hours, so the 20.30% jump likely reflects either a delayed market reaction to an earlier announcement, a technical or sentiment-driven move in this lower-priced equity, or news not yet indexed by the RSS feed.

Boxabl is a modular housing company that trades at a relatively low price point and likely has a smaller public float, characteristics that can make such stocks more susceptible to technical momentum, retail interest, or delayed reaction to company announcements. The complete absence of headlines in the last 48 hours despite a significant intraday gain suggests either that the catalyst occurred before the news snapshot window, that an official announcement has not yet been widely picked up by major financial feeds, or that the move is driven primarily by technical factors or sentiment shifts rather than new fundamental information. For a specialized manufacturing or construction-technology firm like Boxabl, catalysts typically include contract wins, production milestones, guidance updates, or industry tailwinds, but none of these appear in the available headlines.

AMIX

Autonomix Medical, Inc. Common StockHealthcare

$4.57+$0.83

+19.7%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the last 48 hours, so the 19.67% gain on AMIX likely reflects either a delayed market reaction to an earlier announcement, technical momentum, or untracked news sources rather than a freshly reported event.

The absence of recent headlines on Yahoo Finance in the last 48 hours is notable given the stock's strong 19.67% daily gain and ranking as the 20th biggest gainer. This disconnect suggests either that the catalyst is older than the 48-hour window and gained momentum over time, that news broke on channels not captured in this feed, or that the move is driven by technical factors such as short covering, options expiration dynamics, or retail trading activity. Medical device companies like Autonomix Medical can also respond to clinical trial results, regulatory submissions, or partnership announcements that may circulate through specialized channels before appearing in general financial news aggregators. Without access to the underlying news trigger, any explanation remains speculative.

LAD

Lithia Motors IncConsumer Cyclical

$427.48+$69.37

+19.4%

LTCH

Latch, Inc.Technology

$0.18+$0.03

+19.3%

NASDAQ · Mkt cap $31 M

No news headlines were found in the past 48 hours for LTCH, so the 19.26% intraday gain likely reflects either delayed market reaction to unreported developments, technical trading activity in a low-priced stock, or unconfirmed market rumors.

The absence of news in the Yahoo Finance RSS feed over the last two days makes it difficult to pinpoint a specific catalyst for the jump. LTCH is a microcap stock trading at $0.18, a price level where small absolute dollar moves can generate large percentage swings and where technical factors, short covering, or retail trading attention can drive outsized moves independent of fundamental news. The stock could be responding to an earnings report, guidance update, or corporate announcement that has not yet propagated through major financial news feeds, or it could be a momentum-driven move based on chart action or social media discussion. Without access to company filings, press releases, or broader financial news coverage beyond the provided RSS source, identifying the specific trigger is not possible.

BOOM

DMC Global IncIndustrials

$5.42+$1.04

+19.0%

NASDAQ · Mkt cap $150 M

DMC Global reported second quarter earnings on July 29 with $157.0 million in sales and $0.10 diluted EPS, likely driving the 19% intraday gain as investors reacted positively to the results.

The earnings announcement on the snapshot date itself is the most probable catalyst for BOOM's 19% gain. The headline confirms DMC reported Q2 financial results including $157.0 million in quarterly sales, net income of $0.5 million, and adjusted EBITDA of $10.7 million. Without comparative guidance or prior-year figures in the provided headline, I cannot determine whether these results beat or missed expectations. However, the timing of the announcement matching the trading date, combined with the stock's ranking as the 23rd biggest gainer, suggests investors received the earnings favorably. This could reflect better-than-expected performance, improved guidance, margin expansion, or positive commentary on forward conditions. The magnitude of the gain indicates meaningful positive sentiment rather than modest reassessment.

ATXI

Avenue Therapeutics IncHealthcare

$0.36+$0.06

+18.7%

NASDAQ · Mkt cap $824 K

No news headlines were found in the last 48 hours, so the 18.7% gain likely reflects either delayed market reaction to an earlier announcement, technical trading, or an undisclosed corporate development not yet picked up by major news feeds.

Avenue Therapeutics is a small-cap biopharmaceutical company trading at $0.36, and the absence of recent headlines makes attribution difficult. For micro-cap biotech stocks, price moves of this magnitude can occur from several sources: late-stage clinical trial results or FDA decisions announced yesterday that have not yet appeared in the Yahoo Finance feed, short covering or technical momentum in a thinly traded security, insider activity or block trades, or forward-looking market anticipation of an announcement expected imminently. Without access to press releases directly from the company or real-time market data showing unusual volume or options activity, we cannot determine which of these mechanisms drove today's move. The lack of headline coverage within 48 hours is notable but does not rule out a legitimate corporate catalyst.

EVAC.WT

EQV Ventures Acquisition Corp II WT

$0.39+$0.06

+18.6%

EXLS

ExlService Holdings IncTechnology

$36.06+$5.54

+18.2%

NASDAQ · Mkt cap $5.6 B

ExlService reported a strong Q2 2026 earnings beat with revenue up 15.6% year-over-year and raised full-year guidance, while adjusted EPS jumped 22.3%, directly triggering the 18% single-day gain.

ExlService delivered multiple positive surprises on 2026-07-28 after market close. Revenue of $594.8 million exceeded analyst expectations by 3.59%, while earnings beat by 7.27%. The company posted adjusted diluted EPS of $0.59, up 22.3% from $0.49 in the prior-year quarter, significantly outpacing the 4.9% growth in GAAP EPS. Management highlighted accelerating growth across all operating segments and notably emphasized strength in AI and data analytics, an area of intense investor focus. The company also raised its full-year revenue guidance despite acknowledged headwinds in digital operations and macro uncertainty. This combination of beat-and-raise is a classic catalyst for large single-day gains in business services stocks, particularly when paired with commentary signaling structural tailwinds from emerging technologies.

BLKB

Blackbaud IncTechnology

$42.36+$6.43

+17.9%

NASDAQ · Mkt cap $2.2 B

Blackbaud reported strong Q2 2026 earnings with a 46% increase in free cash flow, beat earnings estimates by 8.13%, launched new AI products, and guided toward the upper half of full-year guidance ranges, driving the 17.88% gain.

All seven news items published on July 29, 2026 are centered on Blackbaud's second-quarter earnings announcement released that morning. The company delivered multiple positive catalysts simultaneously: earnings beat of 8.13%, significantly improved free cash flow growth, and continued investment in AI-powered solutions that the market views favorably. Management reaffirmed and raised near-term expectations by pointing investors to the upper end of full-year guidance ranges. The consistent messaging across multiple financial news outlets about robust cash flow generation and AI product expansion suggests the market is responding to both near-term beat evidence and confidence in future growth drivers. The timing of all headlines on the same day confirms this is an earnings-driven move.

CBZ

CBIZ IncIndustrials

$54.90+$8.20

+17.6%

NYSE · Mkt cap $3.0 B

CBIZ jumped 17.56% following announcement of a $5 billion acquisition by Grant Thornton Advisors at $55 per share, a 54% premium to the 30-day volume-weighted average price, announced during market hours on July 29.

The acquisition deal is the clear driver of the stock surge. Multiple headlines confirm that Grant Thornton Advisors agreed to acquire CBIZ in an all-cash transaction valuing the company at $5 billion, with shareholders receiving $55 per share. This represents a substantial premium to recent trading levels and would create the fifth-largest professional services firm in the U.S. The deal was announced mid-day on July 29, which explains the timing of the intraday gain and the jump to the final close price of $54.90. The announcement occurred despite CBIZ missing Q2 revenue estimates and facing a broader decline in financial sector stocks that day, demonstrating that the acquisition premium overwhelmed negative earnings guidance concerns. The 17.56% gain aligns closely with the 54% premium cited, adjusted for the stock's recent trading range.

STAK

STAK Inc. Ordinary SharesEnergy

$2.42+$0.33

+16.3%

NASDAQ · Mkt cap $29 M

No news headlines were found in the last 48 hours for STAK, so the 16.34% gain likely reflects technical trading, market rumors, or a delayed announcement not yet indexed in the news feed.

The absence of any news in the Yahoo Finance RSS feed over the last two days makes it impossible to tie this move to a specific corporate event like earnings, guidance, an acquisition, or regulatory approval. STAK is a micro-cap or penny stock trading at $2.42, which are vehicles typically subject to high volatility and prone to move on retail sentiment, short covering, or unconfirmed rumors that spread through social media or trading forums before appearing in traditional news outlets. The stock's rank as the 29th biggest gainer suggests broad market participation, which could indicate a brief momentum rally or reversal of prior losses rather than a fundamental catalyst. Without corroborating headlines or insider filings visible here, the true driver remains speculative.

JBDI

JBDI Holdings Limited Ordinary SharesConsumer Cyclical

$1.22+$0.17

+16.2%

NASDAQ · Mkt cap $12 M

No news headlines were available in the last 48 hours, so the 16% gain on JBDI likely resulted from technical factors, short covering, or delayed disclosure of company news not yet picked up by Yahoo Finance.

The absence of any recent news headlines makes it impossible to identify a specific catalyst for the 16.18% jump in JBDI stock. This sharp single-day move in a micro-cap name (trading at $1.22) could reflect several common patterns. Penny stocks and small-cap equities are prone to short squeezes when accumulated short positions unwind, technical breakouts from chart formations, or delayed announcement lag where company news reaches trading desks before broad media distribution. Alternatively, sector tailwinds, insider buying, or preliminary acquisition interest could drive moves before formal disclosure. Without access to the company's recent filings, insider transactions, or confirmed news through other channels, the specific mechanism remains unclear.

GRMN

Garmin LtdTechnology

$294.84+$41.06

+16.2%

NYSE · Mkt cap $53 B

Garmin beat Q2 earnings expectations significantly, raising full-year guidance, which drove the 16% surge despite a broader market decline on Fed rate decisions and geopolitical tensions.

The headlines establish that Garmin announced second-quarter results on 2026-07-29 with an adjusted earnings beat of $2.81 per share versus the $2.30 consensus estimate, representing a 23.79% earnings surprise. The company also raised its full-year outlook. This performance was strong enough to push Garmin into $50 billion market cap territory. The stock surged 16% on these results despite a difficult broader market environment: the S&P 500 fell as the Federal Reserve held rates steady for a fifth consecutive meeting, and oil prices spiked following Iran's missile attack. The fact that Garmin gained sharply while the overall market declined underscores that company-specific positive fundamentals drove the move rather than macroeconomic tailwinds. Revenue also beat estimates by 4.73%, though the earnings beat was the headline catalyst.

PRCH

Porch Group, Inc.Technology

$12.36+$2.03

+16.0%

NASDAQ · Mkt cap $2.1 B

Porch Group's second quarter 2026 earnings results, which exceeded expectations, likely drove the 16% intraday gain, though the full details of the beat are truncated in the provided headline.

On July 29, 2026, Porch Group announced its Q2 2026 earnings results, with the Yahoo Finance headline explicitly stating the results "exceeded" expectations. The timing of the announcement (20:02 UTC, after market close) and the magnitude of the same-day gain (16.02%, ranking 32nd among daily gainers) strongly suggest the market reacted positively to this earnings release. However, the headline text provided is incomplete—it cuts off mid-sentence before revealing the specific metrics that drove the beat, such as revenue growth, profit margins, user acquisition, underwriting performance, or forward guidance changes. For a homeowners insurance company like Porch, investors typically focus on premium volume, loss ratios, combined ratios, and growth in the digital channels. Without the full earnings details, we can reasonably infer the company delivered better-than-expected financial performance, but the precise drivers remain unknown.

ALISR

Calisa Acquisition Corp Right

$0.58+$0.08

+15.7%

NASDAQ

No news headlines were published in the last 48 hours for ALISR, so the 15.75% gain likely reflects a technical or structural move common to SPAC rights or a delayed market reaction to an earlier announcement not captured in the recent feed.

Calisa Acquisition Corp Right (ALISR) is a SPAC rights unit, a security that behaves distinctly from common equity. Rights tend to exhibit higher volatility and can move sharply on illiquidity, small-share trades, or shifts in the underlying SPAC's prospects or merger timeline. Without recent headline coverage, the jump could stem from several non-news drivers: a bulk trade in thin volume, arbitrage activity between the rights and the parent unit, news released before the 48-hour window, or updated sentiment about the SPAC's merger target or completion timeline. Low-priced rights are also vulnerable to technical rallies and retail interest. Without accompanying headlines, attribution is speculative.

AVTR

Avantor IncHealthcare

$14.38+$1.94

+15.5%

NNNN

Anbio Biotechnology Class A Ordinary SharesHealthcare

$11.56+$1.54

+15.4%

NASDAQ · Mkt cap $366 M

No news headlines were reported in the last 48 hours, so the 15.37% gain cannot be attributed to a specific announced event. The move likely reflects either delayed market reaction to prior news, technical buying, or a clinical or business development catalyst not yet picked up by major news feeds.

Anbio Biotechnology showed a strong single-day gain of 15.37% on July 29, 2026, ranking among the day's top 35 gainers, yet no news headlines appeared in the last 48 hours on Yahoo Finance. This disconnect between price action and available news coverage suggests several possibilities. First, a material announcement or data release may have occurred but not yet been indexed by the news aggregator. Second, the move could reflect a delayed market reaction to an event from earlier in the week. Third, for a biotech stock like Anbio, the catalyst could be a clinical trial result, regulatory filing, partnership announcement, or insider activity that moves the stock before widespread media coverage catches up. Without concurrent headlines, attributing causation is speculative, though biotech stocks are known to respond sharply to clinical and regulatory events.

SKYQ

Sky Quarry Inc.Energy

$4.51+$0.61

+15.2%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours for Sky Quarry Inc., so the 15.23% gain cannot be attributed to a specific disclosed catalyst and likely reflects technical trading, delayed news pickup, or market speculation.

Sky Quarry Inc. posted a strong 15.23% single-day gain on July 29, 2026, ranking it among the top 36 gainers on NASDAQ, but zero news headlines appeared in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect suggests the move was not driven by a major announced event such as earnings, guidance, contract awards, or corporate actions that would typically generate immediate press coverage. For a micro-cap or small-cap stock like SKYQ, possible catalysts include technical rebounds after oversold conditions, short-covering rallies, social media-driven retail attention, sector rotation momentum, or potentially a press release that had not yet reached major financial news aggregators at the time of this snapshot. Without access to the company's investor relations pages, SEC filings, or real-time social media signals, we cannot identify which mechanism drove this move.

RCKY

Rocky Brands IncConsumer Cyclical

$49.02+$6.47

+15.2%

NASDAQ · Mkt cap $352 M

Rocky Brands reported Q2 2026 revenue growth of 12%, its strongest rate since 2022, driven by direct-to-consumer sales and broad footwear gains, triggering a 15.21% single-day jump as the market rewarded the earnings beat.

Rocky Brands announced second-quarter results on July 28-29 showing 12% revenue growth, characterized as the company's strongest growth rate since 2022. The earnings call highlights emphasized robust direct-to-consumer sales and strategic brand expansions across its footwear portfolio. The company appears to have offset tariff-related cost pressures through operational strength and channel mix. This represents a substantive positive earnings report that would naturally trigger institutional and retail buying. The timing of the jump (earnings released evening of July 28, stock up 15% by July 29 market open) aligns cleanly with the announcement. No guidance revision or forward-looking commentary is detailed in the headlines, but the earnings beat itself appears sufficient to explain the magnitude of the move given RCKY's prior trading history.

YHC

LQR House Inc.Consumer Defensive

$1.61+$0.21

+15.0%

NASDAQ · Mkt cap $2.2 M

No news headlines were found in the last 48 hours for YHC, so the 15% gain on July 29 cannot be attributed to a specific announced catalyst. The move likely reflects either technical momentum, sector rotation, or undisclosed corporate developments.

YHC jumped 15% to $1.61 with no corresponding financial news in the Yahoo Finance RSS feed over the preceding two days. For a micro-cap stock trading near $1.60, moves of this magnitude are common and can be driven by several non-headline factors. Thin trading volumes typical of sub-$2 stocks can amplify price swings from modest buying interest. Additionally, small-cap spirits and beverage companies occasionally respond to sentiment shifts around FDA or TTB regulatory developments, activist investor activity, or earnings pre-announcements that may circulate on OTC boards or company channels before formal press release distribution. Without access to real-time order flow, SEC filings, or social media discussion, we cannot pinpoint the specific driver. The absence of headlines does not rule out a legitimate corporate event; it only means it was not captured in the RSS feed sampled.

OTLK

Outlook Therapeutics IncHealthcare

$1.02+$0.13

+14.9%

NASDAQ · Mkt cap $167 M

Outlook Therapeutics surged 14.94% following FDA approval of LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration, the company's first approved ophthalmic treatment and entry into a multibillion-dollar market.

The headline from July 29 explicitly confirms that the FDA approved LYTENAVA for treating neovascular age-related macular degeneration, making it the first ophthalmic bevacizumab formulation cleared for this indication. This represents a major milestone for Outlook Therapeutics, transforming the company from a clinical-stage firm into one with an approved commercial product targeting a large patient population. The second headline from July 28 references the same FDA approval and characterizes it as targeting a multibillion-dollar ophthalmology market, suggesting substantial commercial opportunity. For a smaller biotech company, FDA approval is a transformational event that typically triggers significant revaluation. The 14.94% single-day gain is consistent with investor enthusiasm around the regulatory clearance and the associated de-risking of the company's lead asset, though without specifics on guidance, launch timing, or competitive positioning, we cannot assess whether the valuation is sustainable.

VCIG

VCI Global Limited - Ordinary ShareIndustrials

$0.39+$0.05

+14.8%

NASDAQ · Mkt cap $2.4 M

No news headlines were found in the last 48 hours, so the 14.81% gain likely reflects technical trading activity, a delayed market reaction to an earlier announcement, or sector-wide momentum in micro-cap stocks.

VCI Global is a micro-cap stock trading at $0.39 with no recent news on file to explain today's 14.81% jump. Stocks at this price point and market capitalization tier are typically thinly traded and prone to outsized percentage moves on relatively modest dollar volume, technical breakouts, short covering, or delayed market processing of earlier announcements that may not yet have propagated through major news feeds. Without access to intraday volume data, sector rotation trends, or any substantive catalyst, the move remains unexplained by available headlines. The absence of news within 48 hours does not rule out an older announcement gaining traction or pure technical/momentum factors driving the gain.

WBUY

WEBUY GLOBAL LTD. - Ordinary SharesConsumer Cyclical

$1.02+$0.13

+14.3%

NASDAQ · Mkt cap $4.2 M

No news headlines were found in the last 48 hours for WBUY, so the 14.29% gain likely reflects technical trading, a delayed announcement, or market speculation rather than a specific disclosed catalyst.

WEBUY Global Ltd. jumped 14.29% to $1.02 on July 29, 2026, but no news appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This disconnect between price action and reported headlines is common for low-priced stocks, which are susceptible to several non-fundamental drivers. First, thin liquidity and low share count can amplify intraday moves on modest volume; a small institutional buy or short covering can trigger outsized percentage gains. Second, micro-cap stocks often respond to news released on company websites, SEC filings, or alternative channels that do not appear immediately in mainstream feeds. Third, the stock's low price point ($1.02) makes it a candidate for retail-driven momentum or technical chart breakouts. Without specific evidence of an announcement, earnings beat, or business development, the most probable explanations are technical momentum, a delayed news lag in the RSS feed, or speculative repositioning.

SCL

Stepan CoBasic Materials

$65.99+$8.03

+13.9%

NEO

NeoGenomics IncHealthcare

$15.27+$1.85

+13.8%

NASDAQ · Mkt cap $2.0 B

NeoGenomics surged 13.79% on strong Q2 earnings, with revenue beating expectations, margin expansion, and raised full-year 2026 guidance across both revenue and adjusted EBITDA.

NeoGenomics reported second-quarter revenue of $201.7 million, up 11.2% year-over-year and exceeding prior outlook. The earnings call highlights emphasize robust revenue growth, margin expansion, and higher-value clinical testing driving performance. Most importantly, the company raised its full-year 2026 guidance for both total revenue and adjusted EBITDA. While the news mentions challenges in the pharma segment, the beat on the top line combined with proactive guidance raises—a signal of management confidence—typically drives significant single-day gains in healthcare diagnostics stocks. The timing of the earnings release (July 28 after hours) aligns with the July 29 trading action. Note that healthcare sector indices were softer late Wednesday, but NEO's outsized gain suggests investors rewarded the company-specific catalysts over sector weakness.

CAKE

Cheesecake Factory Inc-TheConsumer Cyclical

$101.12+$12.16

+13.7%

NASDAQ · Mkt cap $5.3 B

Cheesecake Factory beat Q2 earnings expectations significantly, reporting its first $1 billion quarterly revenue and 25% net income growth, driving a 13.67% stock surge on strong operational momentum.

The headlines establish that Cheesecake Factory released Q2 2026 earnings results on July 28-29 that exceeded Wall Street estimates on both revenue and earnings per share. Specifically, the company surpassed $1 billion in quarterly revenue for the first time, achieved a 23% EPS beat and 3.1% revenue beat versus consensus, and reported 25% year-over-year net income growth to a record $68 million. Same-store sales grew 5.8% in the quarter. Multiple sources describe the results as demonstrating strong momentum and improving profitability in the casual-dining segment. One headline notes the earnings beat has drawn attention to the broader restaurant stock sector, including comparisons to Shake Shack. The magnitude of the gain (13.67%) aligns with a combination of surprise upside on both top and bottom lines plus achieved milestone metrics (the $1 billion threshold) that likely signal improved operational leverage and consumer demand recovery in that subsector.

Goldfield Corp-TheConsumer Defensive

$0.21+$0.03

+13.7%

NASDAQ · Mkt cap $157 K

The news headline provided references Visionary Holdings' subsidiary entering a distribution agreement in China for stem cell products, but no direct connection to Goldfield Corp (GV) is established in the available text, leaving the cause of today's 13.66% gain unclear.

The single headline discusses Nanjing Tuoyuanjian Health Technology (a Visionary Holdings subsidiary) partnering with Suncare for distribution of stem cell aesthetic products in China. There is no explicit mention of Goldfield Corp or GV in the headline text provided. This creates ambiguity about whether the news is actually related to today's move. Goldfield Corp is traditionally a mineral exploration and mining company, making a stem cell healthcare partnership an unlikely direct business catalyst. The gain could reflect investor confusion between ticker symbols, a delayed market reaction to unrelated company news, technical momentum in a micro-cap stock trading at $0.21, or an undisclosed corporate development not captured in the headlines supplied. Without clearer information linking this headline to GV specifically, the true catalyst remains speculative.

ZTG

Zenta Group Company LimitedIndustrials

$2.72+$0.37

+13.6%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours for ZTG, so the 13.59% gain cannot be directly attributed to a reported announcement or disclosure. The move may reflect technical trading, delayed news propagation, or market speculation.

The absence of recent headlines in the 48-hour window preceding this 13.59% jump makes it impossible to tie the gain to a specific corporate event such as earnings, product approval, partnership announcement, or guidance change. For a small-cap stock like ZTG trading at $2.72, large percentage moves can occur from several non-news-dependent sources: short covering or a reversal of prior selling pressure, increased retail or algorithmic trading activity, options-related hedging flows, or a delayed reaction to older news not captured in the most recent RSS feed. Without access to level-two order data, insider trading, or broader market context for the day, we cannot determine whether this was demand-driven or technically driven, nor whether it represents a sustained repricing or a temporary fluctuation.

SMTI

Sanara MedTech Inc.Healthcare

$30.25+$3.60

+13.5%

NASDAQ · Mkt cap $314 M

MIMEDX announced it will acquire Sanara MedTech, which directly explains the 13.51% gain in SMTI stock as investors priced in the merger premium and strategic value of the combination.

The headlines confirm that MIMEDX Group announced plans to acquire Sanara MedTech on July 29, 2026, describing it as a transformational combination that creates a leading regenerative medicine company and nearly doubles MIMEDX's surgical revenue. This is a clear M&A catalyst. When a smaller public company is acquired by a larger peer, the target stock typically rallies toward the deal price. The magnitude of the move (13.51%) suggests the market views the combination favorably and that the deal price represents a meaningful premium to recent trading levels. MIMEDX also reported Q2 2026 results with $64 million in net sales and reiterated full-year guidance on a standalone basis, though the acquisition announcement is the primary driver of SMTI's jump. No details on deal terms were provided in the headlines, but the strategic rationale of expanding surgical footprint and combining regenerative medicine platforms appears to have resonated with investors.

MTC

MMTEC IncFinancial Services

$3.79+$0.45

+13.5%

NASDAQ · Mkt cap $309 M

No news headlines were found in the last 48 hours for MTC, so the 13.47% gain on July 29 cannot be attributed to a specific disclosed event; the move likely stems from technical trading, a delayed announcement, or market rumors not yet captured in major news feeds.

MTC (MMTEC Inc) jumped 13.47% to rank 48th among daily gainers, yet no headlines from Yahoo Finance appeared in the prior 48 hours to explain the move. This absence of news is itself significant. Small-cap and micro-cap stocks like MTC can spike on several types of catalysts that may not immediately generate major press coverage: short covering or technical breakouts, social media momentum, after-hours announcements or press releases not yet syndicated to major feeds, sector rotation into small-cap technology or related segments, or trading volume anomalies. Without access to real-time trade data, option flow, or company press releases outside the Yahoo Finance RSS feed, we cannot pinpoint the trigger. The stock's rank among daily gainers suggests genuine volume and interest rather than pure noise, but the cause remains unidentified.

JELD

JELD-WEN Holding IncIndustrials

$1.29+$0.15

+13.2%

NYSE · Mkt cap $177 M

JELD-WEN jumped 13.22% likely on the release of its 2025 Sustainability Report, which may have signaled positive ESG progress or operational improvements to investors seeking evidence of management execution and long-term value creation.

On July 28, JELD-WEN published its 2025 Sustainability Report highlighting environmental, social, and governance progress across global operations. The timing and magnitude of the 13.22% gain the following day suggest this disclosure resonated with markets, though the headline provided does not detail specific metrics, targets, or breakthroughs. It is reasonable to infer that the report may have contained positive ESG credentials, cost-efficiency gains, or strategic milestones that reassured investors about management competence and regulatory positioning. However, without access to the full report or analyst commentary, the exact driver remains unclear. The move could also reflect technical factors, short covering, or delayed market reaction to an earlier catalyst not captured in the headline snippet.

DSX.WT

Diana Shipping Inc. WT

$0.17+$0.02

+13.2%

Biggest Losers

Wed, Jul 29, 2026 50

YYAI

Connexa Sports Technologies Inc.Technology

$0.29−$0.62

-68.0%

BIOT

Biotech Acquisition CompanyConsumer Defensive

$0.56−$0.74

-56.9%

ZONE

CleanCore Solutions IncIndustrials

$0.32−$0.39

-55.2%

NYSE · Mkt cap $34 M

CleanCore announced a major 10-year AI data center colocation deal with Cerebras and appointed a new CEO within 48 hours, yet the stock plummeted 55%, suggesting market skepticism about execution, valuation, or undisclosed negative developments.

The two headlines appear positive on their face: a decade-long colocation agreement with an AI infrastructure player and new leadership focused on AI buildout. However, the 55% single-day loss is severe enough to indicate the market either views these announcements as insufficient to justify current valuation, harbors concerns about the Cerebras partnership terms (duration or revenue certainty), doubts the new CEO's ability to deliver, or has reacted to information not visible in these headlines. For a micro-cap stock like ZONE trading at $0.32, liquidity is thin and sentiment can swing sharply on perceived dilution, guidance shortfalls, or secondary offerings. The timing of leadership change alongside a major contract can also spook investors if they infer instability. Without earnings data, balance sheet details, or explicit negative guidance in the provided headlines, the root catalyst remains unclear, though contract terms or capital structure concerns are reasonable hypotheses.

LMNX

Luminex CorpFinancial Services

$7.31−$7.67

-51.4%

DAIC

CID HoldCo, Inc.Technology

$0.69−$0.52

-46.4%

NASDAQ · Mkt cap $508 K

No news headlines were reported in the last 48 hours for DAIC, so the 46% single-day drop likely reflects either a delayed market reaction to an earlier announcement, a technical/liquidity event, or an untracked development such as an insider move or exchange delisting notice.

The absence of any recent news headlines in the search results means the cause of this dramatic 46% decline cannot be directly attributed to a specific announcement or event captured in public financial news feeds. For a microcap or thinly-traded security like DAIC trading at $0.69, common catalysts for such moves include: (1) a prior press release or SEC filing that the market is just pricing in with a lag; (2) a liquidity crunch or forced liquidation by a major holder; (3) an earnings miss or guidance cut that was announced outside the 48-hour window; or (4) technical selling or short-covering activity. Without access to the company's investor relations page or real-time SEC filings for the period immediately before the snapshot date, it is not possible to pinpoint which category applies here.

ALCE

Alternus Clean Energy, Inc.Utilities

$0.06−$0.05

-42.9%

NASDAQ · Mkt cap $43 K

ALCE dropped 42.86% with no news headlines in the last 48 hours, making the immediate catalyst unclear; the move likely stems from technical selling, sector weakness, or untracked developments in the renewable energy or microcap space.

No Yahoo Finance headlines appeared in the 48 hours preceding this sharp decline, so there is no news-based explanation available from the provided data. ALCE is a microcap clean energy stock trading at $0.06, which makes it sensitive to liquidity constraints, retail trading flows, and sentiment shifts. Stocks in this category often experience large percentage swings on low volume and without announced catalysts. The 42.86% drop could reflect broader renewable energy sector pressure, forced liquidations, a delayed news event not yet indexed by Yahoo's feed, or purely technical momentum reversal. Without access to intraday volume data, short interest levels, or competing news sources, we cannot pinpoint the specific cause.

PCSA

Processa Pharmaceuticals, Inc.Healthcare

$2.02−$1.20

-39.6%

NASDAQ · Mkt cap $7.0 M

Processa announced a major acquisition of Vidya Therapeutics and secured $200 million in financing on July 29, but the stock fell 39.62%, suggesting market concern about dilution, valuation, or execution risk despite the strategic pipeline addition.

The headlines report a significant M&A event: Processa acquired Vidya Therapeutics and closed a concurrent $200 million private placement. On the surface, this appears strategically positive—it adds a clinical-stage BTK inhibitor (VT-7208) to the pipeline and provides funding through 2029. However, the severe single-day decline indicates the market reacted negatively. Common reasons for such reactions in biotech M&A include: substantial shareholder dilution from the private placement at a discount to market price, concern that the acquisition price was too high relative to asset quality, worry that pipeline integration will consume resources without near-term revenue generation, or skepticism about the company's ability to execute on multiple BTK programs simultaneously. Without details on placement pricing, share count impact, or acquisition consideration, the exact source of the sell-off cannot be pinpointed, but dilution from the concurrent financing is a leading hypothesis given typical biotech market behavior.

MBRX

Moleculin Biotech IncHealthcare

$1.36−$0.85

-38.4%

NASDAQ · Mkt cap $4.3 M

No news headlines were found in the last 48 hours, so the 38% drop likely reflects an earnings miss, clinical trial setback, dilutive financing announcement, or other material event that has not yet surfaced in the RSS feed.

Moleculin Biotech is a small-cap biotech company, and a single-day 38% decline ranks it among the day's largest losers. Without headlines in the provided feed, the catalyst is not immediately identified through public news sources. However, for companies in this sector and market cap range, the most common catalysts for such severe declines are adverse clinical trial results, unfavorable regulatory decisions, unexpected dilutive equity offerings, cash runway concerns, or executive departures. It is also possible that material news was released but has not yet been indexed by the RSS feed, or that the move reflects a delayed market reaction to earlier announcements. Technical selling or options-driven dynamics cannot be ruled out for illiquid names, though this is less likely to be the sole driver of a 38% drop.

DAAQ

Digital Asset Acquisition Corp.Financial Services

$7.15−$4.00

-38.1%

NASDAQ · Mkt cap $239 M

No news headlines were published in the last 48 hours, so the cause of the 38.10% drop cannot be determined from available reporting. The decline likely stems from either a significant unreported corporate event, technical selling, or market sentiment shift affecting the SPAC.

Digital Asset Acquisition Corp. is a blank-check company (SPAC), and a drop of this magnitude without accompanying news is notable. SPACs are sensitive to changes in merger prospects, redemption dynamics, and liquidity conditions. Possible explanations include a delayed announcement of a failed merger negotiation, significant redemptions ahead of a shareholder vote, a letter or filing released after market hours yesterday that markets are now pricing in, or broad sector rotation away from digital asset-related blank-check vehicles. Without current news coverage, we cannot definitively link the move to a specific catalyst, but SPACs frequently experience sharp moves on transaction updates or sponsor activity.

SLXN

Biomotion SciencesHealthcare

$1.61−$0.94

-36.8%

NASDAQ · Mkt cap $540 K

SLXN dropped 36.81% despite announcing successful initiation of a Phase 2/3 clinical trial for SIL204 in pancreatic cancer, suggesting the market reaction was driven by factors other than the positive trial news disclosed.

The provided headline announces a positive clinical development—successful initiation of Phase 2/3 testing at a major Israeli medical center—which would normally support or buoy a biotech stock price rather than trigger a severe decline. The magnitude of the drop (36.81%) ranking it among the day's ten worst performers indicates a more material adverse event or disclosure occurred. Possible explanations include a separate earnings miss, guidance reduction, capital raise announcement, pipeline setback in another program, management change, or adverse regulatory communication not captured in the single headline provided. The disconnect between the positive news and the sharp sell-off suggests either the trial initiation was priced in and masked by simultaneous negative information, or critical information driving the decline is absent from the available headlines.

PSN

Parsons CorpTechnology

$40.32−$21.68

-35.0%

NYSE · Mkt cap $5.1 B

Parsons crashed 35% after cutting full-year revenue guidance to $6.2-6.5B from $6.5-6.8B and reporting a Q2 loss that missed earnings expectations by 108%, despite beating on some operational metrics like bookings.

The headlines establish that Parsons reported Q2 2026 earnings on July 29 with a significant earnings miss (negative 108% surprise) and flat year-over-year revenue of $1.58B, trailing Wall Street expectations. Most critically, the company slashed its full-year 2026 revenue guidance downward, a material reduction that typically triggers sharp selloffs in defense and infrastructure contractors. One headline notes investors are "emphasizing something else altogether" despite a bottom-line beat, pointing specifically to the guidance cut as the dominant driver. While the company touted strong bookings (24% YoY growth in contract awards and a 1.2x book-to-bill ratio), these forward-looking positives were overwhelmed by the backward revision in full-year outlook. The $2.6B valuation loss and ranking as the 11th worst performer of the day confirms this was a market-wide repricing on reduced earnings expectations.

RDGT

Ridgetech IncHealthcare

$0.76−$0.40

-34.1%

NASDAQ · Mkt cap $2.9 M

No news headlines were available in the last 48 hours for RDGT, so the 34% intraday drop cannot be attributed to a specific disclosed catalyst; the decline likely reflects a market-moving event not yet covered in public feeds or reflects trading in a low-liquidity microcap stock.

The absence of recent news headlines makes it impossible to identify a concrete cause for Ridgetech's sharp 34% decline on July 29. For a stock trading at $0.76 with this severity of move, several categories of catalyst are typical. First, a company-specific announcement such as adverse clinical or product results, a dilutive capital raise, insider departure, or missed guidance might have occurred but not yet propagated to headline feeds; this is common for microcap stocks. Second, the stock could have experienced a technical washout or margin-related selling unrelated to fundamental news. Third, a delayed market reaction to a prior announcement or a development in a thinly traded name could amplify the move. Without access to the company's investor relations channels or the full news wire, any specific cause remains inference rather than fact.

BAND

Bandwidth IncTechnology

$36.96−$15.26

-29.2%

NASDAQ · Mkt cap $1.5 B

Bandwidth delivered a surprise return to profitability with record revenue, beat guidance, and raised full-year outlook, yet the stock plummeted 29% anyway—a classic "sell the news" reaction despite fundamentally positive results.

The earnings headlines universally confirm strong Q2 2026 performance: net income of $2.4 million versus prior-year loss, revenue of $219.9 million (up 22.2% YoY), beats on both earnings and revenue, and raised full-year and Q3 guidance citing strong demand for AI-enabled communications and enterprise wins. One headline explicitly notes the paradox, asking "Is It Fully Valued?" suggesting the market may have already priced in the recovery and growth narrative. The sharp 29% drop despite objectively positive news points to valuation concerns, potential profit-taking after a likely pre-earnings rally, or investor disappointment that the beat and raise were insufficient to justify current multiples. Without access to forward guidance specifics, exact margin trends, or analyst call commentary, we cannot pinpoint whether guidance raised fell short of whisper expectations or if the market simply decided the stock had run too far ahead of fundamentals.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.02−$0.01

-28.3%

NASDAQ · Mkt cap $1.1 M

No news was reported in the last 48 hours, so the 28% drop likely stems from technical selling, broader market weakness, or an undisclosed company development not yet picked up by financial media.

The absence of any headlines in the last 48 hours makes it impossible to pin a specific news catalyst to today's sharp 28% decline in WTER stock. For a micro-cap stock trading at $0.02, price action is often driven by thin liquidity, retail trading patterns, short covering or accumulation, or broader sector rotation rather than fundamental news. Alkaline Water is a consumer beverage company in a competitive category, and penny stocks in this space can be volatile on minimal volume. The move could reflect delayed reporting of internal developments, a missed filing deadline, shareholder dilution concerns, or simple technical breakdown on a weak bid. Without contemporaneous reporting, the specific trigger remains unknown.

APUS

Apimeds Pharmaceuticals US, IncHealthcare

$5.75−$2.25

-28.1%

NYSE · Mkt cap $6.0 M

No news headlines were found in the past 48 hours, so the 28% drop likely stems from an unannounced catalyst such as an earnings miss, clinical trial setback, insider selling, or broad market condition affecting small-cap pharma stocks.

The absence of any news in the Yahoo Finance RSS feed over the last two days makes it impossible to pinpoint a specific catalyst for APUS's sharp 28% decline. For a small pharmaceutical company, typical drivers of such magnitude moves include unexpected clinical trial results, FDA regulatory action, earnings surprises, insider transactions, analyst downgrades, or liquidity events. The stock's position as the 15th biggest loser suggests material negative information likely reached the market, but without headline confirmation it may have been communicated via SEC filings, company disclosures, or third-party reporting not yet captured in the RSS feed. The timing gap between the move and available news coverage is notable and warrants checking the company's latest 8-K filing or press releases directly.

USDEW

StablecoinX Inc. Warrants

$0.37−$0.14

-28.0%

TGE.WT

The Generation Essentials Group

$0.13−$0.05

-27.8%

NYSE

No news headlines were found in the last 48 hours, so the 27.78% drop cannot be tied to a specific announced catalyst. The move likely reflects either technical selling pressure, broad sector weakness, or an undisclosed corporate event.

The absence of recent headlines makes direct attribution impossible. TGE.WT is a warrant, a leveraged derivative security that magnifies moves in its underlying common stock. Warrants are sensitive to time decay, implied volatility shifts, and deterioration in the underlying equity's value. This 27.78% single-day loss could stem from several sources: sharp weakness in the underlying common stock, a spike in redemption risk or bankruptcy concerns that would collapse warrant value, a dividend or capital event announced without immediate press coverage, or a broader delisting or restructuring threat. Warrant holders face structural hazards that ordinary shareholders do not, including forced exercise deadlines and the possibility of worthlessness if the underlying trades below the strike at expiration. Without news or structural data, we cannot distinguish between these.

CAST

FreeCast, Inc. Class ACommunication Services

$1.21−$0.47

-27.8%

NASDAQ · Mkt cap $100 M

CAST dropped 27.77% despite announcing an expansion into local advertising across 210 TV markets; the disconnect suggests either a pre-existing negative catalyst, a market skepticism about execution, or undisclosed news not captured in the headline.

The single headline from today describes a strategic expansion into the multi-billion-dollar local advertising market with a unified platform—ostensibly a positive development. However, a nearly 28% single-day collapse argues that either this announcement failed to meet market expectations, investors are skeptical of FreeCast's ability to execute on such a platform at scale, or there is material negative information not reflected in the provided headline. The timing of the announcement (released during the trading day) combined with the magnitude of the decline suggests investors reacted unfavorably to either the specifics of the plan, the competitive positioning, financial implications, or guidance context that the headline alone does not convey. Without access to the full press release, earnings report, or competing market conditions, we cannot determine whether the sell-off stems from the announcement itself or from a separate development.

CISS

C3is Inc. - Common StockIndustrials

$0.13−$0.05

-27.7%

NASDAQ · Mkt cap $4.6 M

No news headlines were found in the last 48 hours, so the 27.71% drop cannot be attributed to a specific announced event; the decline likely reflects broader market weakness, technical selling, or unreported company developments.

The absence of any recent news in the Yahoo Finance RSS feed over the past 48 hours makes it impossible to tie this substantial single-day loss to a concrete catalyst like earnings, guidance, regulatory action, or partnership news. For a micro-cap stock trading at $0.13, typical drivers of sharp declines include technical momentum reversal, forced liquidations tied to margin calls or fund redemptions, loss of investor confidence based on delayed filings or missed milestones, promotional activity unwinding, or negative developments announced through channels not captured in the headline feed. Without visibility into company-specific announcements, SEC filings, or social media commentary, the precise cause remains opaque. The ranking as the 19th biggest loser suggests sector-wide or broad-market headwinds may play a role, though individual micro-caps are also prone to outsized moves on minimal volume.

AIIOW

NWTN Inc. WarrantConsumer Cyclical

$0.03−$0.01

-26.4%

NASDAQ

AIIOW (a warrant on AIIO parent Robo.ai) fell 26% likely due to a dilutive joint venture announcement with Abu Dhabi's Eleven International Holdings to form Alif Holding, which may signal equity issuance and reduced near-term warrant upside potential.

The headline documents a joint venture between Robo.ai Inc. (ticker AIIO) and Abu Dhabi-based Eleven International Holdings to establish Alif Holding for AI services in infrastructure and government sectors. AIIOW is a warrant instrument tied to AIIO, meaning its value depends on the underlying stock's performance and volatility. Joint venture announcements often involve new equity issuance or dilution to capitalize the venture, which would reduce the value of existing warrants by increasing share count without an offsetting gain in enterprise value. Warrants are leveraged instruments, so a 26% drop on the parent announcement is plausible if the market views the venture as dilutive or lower-margin. Without explicit language in the provided headline about financing terms or warrant adjustment, the drop likely reflects market concern over dilution and reduced leverage on future AIIO appreciation.

BCAR

D. BORAL ARC ACQUISITION I CORPFinancial Services

$4.15−$1.52

-25.7%

NASDAQ · Mkt cap $226 M

Exascale Labs and BCAR announced shareholder approval of their business combination on July 29, likely triggering a sharp selloff due to post-merger dilution concerns, valuation disappointment, or redemption activity typical of SPAC mergers closing.

The headline confirms that shareholders approved the business combination between Exascale Labs and BCAR on July 29, 2026, the same day as the 25.68% price drop. This timing strongly suggests the market reacted negatively to the merger closing or details disclosed at the shareholder vote. Common drivers of post-SPAC-merger selloffs include: announced redemption rates higher than expected, valuation multiples perceived as expensive, dilution from earnout provisions, or general investor disappointment with the combined entity's near-term prospects. The headline does not provide financial projections, redemption figures, or valuation metrics that would explain the specific magnitude of the decline, but the coincidence of the announcement and the drop is too stark to ignore as unrelated.

SDST

Stardust Power Inc.Industrials

$0.97−$0.32

-24.7%

NASDAQ · Mkt cap $8.6 M

No news headlines were published in the last 48 hours, so the 24.74% drop cannot be attributed to a disclosed event. The decline likely reflects either technical selling, a delayed market reaction to unreported developments, or sector-wide pressure on micro-cap power stocks.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours makes it impossible to pinpoint a specific catalyst for this sharp decline in SDST. For a micro-cap stock trading near $1, typical drivers of single-day losses exceeding 24% include: first, a private development such as failed partnerships, clinical setbacks, or operational issues that has not yet reached public disclosure; second, technical factors like margin calls or algorithmic selling in low-liquidity names; and third, broader sector rotation away from speculative power or energy plays. Without access to real-time market data, insider disclosures, or social media sentiment, we cannot distinguish between these hypotheses. The rank as the 22nd biggest loser suggests significant market attention, which argues against pure technical noise, but without corroborating headlines this remains speculative.

ORN

Orion Group Holdings IncIndustrials

$9.07−$2.92

-24.3%

NYSE · Mkt cap $402 M

Orion Group Holdings reported Q2 earnings that missed estimates due to marine segment project delays, forcing the company to lower guidance despite strong concrete business performance, triggering the 24% sell-off.

The headlines establish that Orion reported Q2 2026 results on July 28-29 with a earnings miss relative to Wall Street expectations. The core issue is marine segment underperformance: project delays reduced volumes and margins in that division. The company responded by adjusting guidance downward to reflect these delays. Management did highlight robust revenue growth overall and a thriving concrete business, but the marine segment deterioration and reduced forward outlook dominated market sentiment. This is a classic earnings-driven sell-off where a major business unit miss and guidance cut overwhelm positive segments, prompting investors to reprice the stock sharply lower. The 24% single-day decline is consistent with material guidance reduction and operational headwinds in a significant revenue stream.

ASBP

PowerUp Acquisition Corp.Healthcare

$5.57−$1.76

-24.0%

NASDAQ · Mkt cap $10 M

No recent news headlines were found to explain the 24% drop in ASBP on July 29, 2026. The decline likely stems from a SPAC-related event, broad market pressure, or private information not yet disclosed publicly.

PowerUp Acquisition Corp. is a blank-check acquisition company, meaning its value depends entirely on its ability to identify and complete a merger with an operating business. SPACs are particularly sensitive to several catalysts: expiration of redemption windows, failed merger negotiations, shareholder votes rejecting proposed deals, regulatory delays, or liquidation announcements. The 24% single-day decline is severe enough to suggest a material corporate event rather than routine trading noise. Without headlines from the last 48 hours, the catalyst could be an announcement made before the news feed was captured, an after-hours filing, or a rumor circulating among informed traders. Market conditions or sector-wide pressure could also contribute, though a 24% drop typically indicates company-specific news for a SPAC.

LEGO.WT

$0.38−$0.12

-24.0%

CBRG

Chain Bridge IFinancial Services

$3.03−$0.95

-23.8%

LMND

Lemonade IncFinancial Services

$47.34−$14.61

-23.6%

NYSE · Mkt cap $4.3 B

Lemonade beat Q2 revenue expectations with 79% year-over-year growth and positive guidance, but the stock crashed 23.58% because investors expected even stronger bottom-line profitability or lower losses than the company delivered.

Lemonade reported Q2 2026 results that exceeded Wall Street's revenue estimates at $294.4 million, up 79.4% year-over-year, along with accelerating in-force premium growth and narrower adjusted EBITDA losses. The company also reaffirmed guidance for stronger next-quarter revenue. Despite these accomplishments and progress on AI-driven efficiency, the stock fell sharply starting in pre-market trading and continued declining through the day. The headlines consistently frame this as a disconnect between operational growth and investor expectations around profitability. The sell-off occurred despite revenue beats, suggesting the market was looking for either positive net income, a smaller loss, or guidance that exceeded the company's actual outlook more substantially. This pattern is typical for growth-stage software and insurance technology companies where investors pivot focus from topline growth to path-to-profitability once revenue reaches certain scale.

TDOC

Teladoc Health IncHealthcare

$9.20−$2.10

-22.8%

MNRO

Monro IncConsumer Cyclical

$13.26−$3.92

-22.8%

NASDAQ · Mkt cap $393 M

Monro reported Q1 fiscal 2027 earnings on July 29 showing a sales decline, lower customer traffic, and consumer caution on higher-ticket repairs, triggering the 22.8% drop as the market repriced expectations for the auto services provider.

Monro announced its first quarter fiscal 2027 financial results on July 29, 2026, which disclosed a year-over-year sales decline of 4.6% to $287.1 million despite meeting revenue expectations. The headlines consistently highlight weak operational conditions: lower customer traffic and consumer hesitancy around higher-ticket repair spending. Management reported a non-GAAP loss of $0.09 per share, significantly below analyst consensus, and an earnings surprise of -325%, indicating the profitability shortfall was material. While company leadership outlined strategic improvements and marketing initiatives for future growth, the immediate financial weakness and deteriorating consumer demand in the automotive repair sector appear to have driven the sharp intraday selloff. The stock's rank as the 29th biggest loser of the day reflects broad market recognition of these disappointing fundamentals.

WLDS

Wearable Devices LtdTechnology

$2.99−$0.81

-22.3%

NASDAQ · Mkt cap $6.0 M

No news headlines were found in the last 48 hours for WLDS, so the 22.28% drop likely stems from technical selling, sector weakness in wearable devices, or undisclosed corporate developments.

The absence of any news headlines in the 48-hour window preceding this significant 22.28% decline makes it impossible to identify a specific announced catalyst. For a microcap wearable device company trading near $3.00, several generic drivers are plausible: broad sector rotation out of consumer electronics or wearables, technical breakdown through a key support level triggering momentum selling, a delayed earnings announcement or guidance cut that has not yet surfaced in Yahoo Finance feeds, insider selling activity, or deteriorating fundamentals not yet publicly disclosed. Without access to real-time trading data, SEC filings, or company communications, this remains speculative. The ranking as the 30th biggest loser suggests the move is not entirely isolated to WLDS alone, which could indicate sector-wide pressure, though that too is inference rather than established fact.

VACI.WT

Viking Acquisition Corp. I WT

$0.70−$0.20

-22.2%

MRDN

Golden Matrix Group, Inc.Consumer Cyclical

$11.01−$3.11

-22.0%

NASDAQ · Mkt cap $169 M

Golden Matrix Group fell 22% despite posting strong Q2 earnings with 16% revenue growth and consecutive quarter of GAAP profitability, suggesting the market may have reacted negatively to sportsbook margin pressures or concerns about the leadership transition announced same day.

The company released three pieces of news on July 29: solid Q2 financial results showing revenue of $50.2 million (up 16% YoY), net income of $2.2 million, and adjusted EBITDA up 43% YoY, plus a leadership change naming Zoran Milosevic as CEO and William Scott as Chairman and CFO. The earnings results appear objectively positive, but the call highlights explicitly mentioned that sportsbook margins were pressured by bettor-friendly conditions. The sharp 22% decline on a day of reported profitability and growth is counterintuitive. Possible explanations include: margin pressure concerns overshadowing revenue growth, market disappointment with margin direction despite earnings beat, or negative interpretation of the simultaneous leadership transition as a sign of internal issues. Without forward guidance details or commentary on margin recovery outlook, investor confidence may have shifted despite the numbers.

AMZE

Fresh Vine Wine, Inc.Technology

$0.18−$0.05

-21.9%

NYSE · Mkt cap $1.5 M

No news headlines were published in the last 48 hours for AMZE, so the 21.94% drop cannot be attributed to any announced event, making the specific cause unknown.

Fresh Vine Wine (AMZE) declined sharply with no supporting news in the most recent 48-hour window. For a micro-cap wine company trading at $0.18, declines of this magnitude are not uncommon and can reflect several typical scenarios: delayed or negative earnings results released before the snapshot window, adverse industry conditions, reduced liquidity creating price volatility, short-seller activity, or loss of investor confidence due to operational setbacks. Without access to news older than 48 hours or real-time market color, the specific trigger remains unclear. Micro-cap stocks in the wine and beverage sector are often thinly traded and sensitive to small order flows, so volume and bid-ask dynamics may have amplified the move independently of fundamental news.

ONFO

Onfolio Holdings Inc. Common StCommunication Services

$0.09−$0.02

-21.2%

NASDAQ · Mkt cap $334 K

Onfolio announced it is exploring strategic alternatives including acquisitions, asset sales, and transformational deals; the market interpreted this as a sign of distress or shareholder dilution risk, driving the stock down 21.2% today.

On July 28-29, Onfolio announced publicly that it is "actively pursuing strategic alternatives" to reshape its portfolio and strengthen earnings. While the language emphasizes value creation, such announcements from small-cap companies trading at $0.09 often signal underlying financial stress, potential dilutive financing needs, or loss of investor confidence in current management strategy. The repeated messaging across three separate headlines within 48 hours suggests the announcement was material and generated sustained selling pressure. The company framed this as proactive portfolio optimization, but the market's -21.2% response indicates investors view strategic alternatives as a euphemism for difficulty in the current operating environment or a precursor to equity dilution through acquisitions or capital raises.

LBGJ

LBGJIndustrials

$0.02−$0.01

-21.1%

NASDAQ · Mkt cap $58 K

No headlines were found in the last 48 hours, so the 21% drop cannot be attributed to a specific disclosed event. Given LBGJ's penny-stock status and illiquid trading profile, the decline likely reflects low-volume technical selling, sector weakness, or undisclosed company developments.

The absence of any news in the 48-hour window before this sharp drop is notable and suggests the catalyst may predate the snapshot, stem from a non-news event (such as options expiration or algorithmic selling in a thinly traded security), or reflect an announcement made through channels not captured by Yahoo Finance RSS. LBGJ trades at $0.02 and ranks 35 among daily losers, indicating meaningful volatility typical of microcap stocks. Penny stocks of this character are sensitive to retail trading activity, short-covering reversals, and liquidity constraints rather than fundamental news flow. The decline could also reflect delayed market reaction to older news, insider selling, or deterioration in a warrant or convertible instrument tied to the underlying company.

RBOT

D8 Holdings Corp.Healthcare

$0.08−$0.02

-21.0%

NYSE · Mkt cap $257 K

No news headlines were found in the last 48 hours for RBOT, so the 21% decline on July 29 cannot be attributed to a specific announced event. The drop likely reflects either technical selling, broader market pressure, or an undisclosed development not yet indexed in major financial feeds.

The absence of recent news headlines is notable given RBOT's severe single-day loss. D8 Holdings Corp trades at a very low price point of $0.08, which typically characterizes either a distressed company, a shell vehicle, or a stock in advanced stages of decline. Penny stocks and ultra-low-priced equities are prone to sharp moves on minimal volume and can gap down due to several hidden catalysts: delayed SEC filings, regulatory compliance warnings, insider selling, convertible debt pressure, or simply technical breakdown of support levels. Without headline confirmation, the most likely explanations fall into two categories: either a catalyst failed to reach major news aggregators before the market moved, or the move is primarily technical and driven by algorithmic or momentum-based selling that doesn't require external news.

LII

Lennox International IncIndustrials

$430.27−$114.02

-20.9%

NYSE · Mkt cap $13 B

Lennox International crashed 21% after cutting its full-year guidance despite beating Q2 earnings estimates, signaling deteriorating residential HVAC market demand ahead despite strong recent recognition for innovation.

Lennox reported Q2 2026 earnings that beat EPS estimates by 1.18% but missed revenue expectations by 1.12%, posting $1.55 billion in revenue with only 3% year-over-year growth. The critical catalyst was the company's decision to cut full-year 2026 guidance, which triggered the sharp selloff described as the worst day in 25 years. Multiple headlines emphasize that despite beating headline numbers, investors reacted negatively to shrinking earnings growth and a challenged residential market outlook. The company's strategic acquisitions and HVAC innovation awards announced earlier were overshadowed by the guidance reduction, suggesting management sees deteriorating demand conditions ahead. A broader market decline on geopolitical oil concerns (Iran missile attack) may have provided additional downward momentum, but the earnings guidance cut is clearly the primary driver of LII's underperformance relative to the market.

FVRR

Fiverr International LtdCommunication Services

$9.21−$2.41

-20.7%

NYSE · Mkt cap $331 M

Fiverr reported weaker-than-expected Q2 earnings and revenue, missed analyst estimates, and sharply cut its full-year 2026 guidance, triggering a 20.7% sell-off.

Fiverr released second-quarter 2026 results on July 29 that fell short on multiple fronts. Revenue came in at $97.78 million, down 10% year-over-year and below Wall Street expectations, with earnings and revenue surprises of -3.85% and -2.59% respectively. More significantly, the company slashed its forward guidance, with Q3 2026 revenue guidance of only $84 million disappointing investors. While management highlighted a strategic shift toward higher-value projects and AI integration as part of a transformation effort, these forward-looking initiatives were insufficient to offset the immediate disappointment. The combination of a revenue miss, earnings miss, and substantially lowered full-year outlook created a perfect storm for a major sell-off, with the stock falling nearly 17% in pre-market trading and closing down over 20%.

RAM

Aries I Acquisition CorporationFinancial Services

$8.43−$1.99

-20.1%

IAUX.WT

i-80 Gold Corp. WT

$0.72−$0.18

-20.0%

ZIVO

Zivo Bioscience, Inc.Healthcare

$4.00−$1.00

-20.0%

NASDAQ · Mkt cap $17 M

No news was published in the last 48 hours about ZIVO, so the 20% decline cannot be directly attributed to a disclosed catalyst. The drop likely reflects broader biotech weakness, technical selling, or unreported developments.

The absence of recent headlines makes it impossible to point to a specific event driving the 20% single-day loss. ZIVO is a small-cap biotech company, and such stocks are sensitive to clinical trial setbacks, financing announcements, insider transactions, regulatory feedback, or shifts in sector sentiment that may not immediately appear in major news feeds. The magnitude of the decline (rank 41 losers) suggests material negative information reached the market, but without access to company filings, SEC forms, private news services, or the company's own investor relations channels updated in the past 48 hours, the precise catalyst cannot be identified from the data provided. Biotech stocks can also gap down on technical breaks or index-wide selloffs in small-cap equities.

EGG

Enigmatig LimitedIndustrials

$3.78−$0.96

-19.8%

NYSE · Mkt cap $87 M

No headlines were available in the last 48 hours to explain EGG's 19.83% decline, so the specific catalyst remains unknown; likely causes include earnings disappointment, insider trading activity, sector weakness, or technical selling.

The absence of recent news headlines makes it impossible to pinpoint a concrete driver for this sharp single-day drop. A nearly 20% intraday loss typically signals material negative information or a significant technical breakdown. Common catalysts for unlisted or smaller-cap stocks without immediate news coverage include disappointing earnings or guidance released after hours or pre-market, insider selling or lockup expiration, broad sector rotation or contagion from sector peers, analyst downgrades not yet reflected in press feeds, or momentum-driven technical selling if the stock was overextended. Without access to earnings calendars, SEC filings, or trading volume data, it is not possible to distinguish between these hypotheses. The rank as 42 biggest loser suggests this was a market-wide negative day or a stock-specific shock rather than purely random noise.

AIXC

Aixcrypto Holdings IncTechnology

$0.65−$0.16

-19.4%

GCDT

Green Circle Decarbonize Technology LimitedIndustrials

$0.35−$0.08

-19.4%

NYSE · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 19.4% drop cannot be directly attributed to a specific announced event; the decline may reflect broader market sentiment, technical selling, or unannounced developments.

The absence of recent news makes it difficult to pinpoint a concrete catalyst for GCDT's sharp 19.4% decline. For a micro-cap decarbonization technology company trading at $0.35, price movements of this magnitude can result from several categories of events: delayed earnings releases or disappointing results that haven't yet appeared in headline feeds, insider selling or secondary offerings that depress share price without immediate disclosure, technical breakdown following previous resistance levels, or broader sector rotation away from green-tech names. Alternatively, the stock may have gapped down on an unannounced company statement, regulatory setback, or contract loss that hasn't yet been picked up by major news aggregators. Without specific news, we are limited to inference about typical catalysts for micro-cap stocks in this space.

FRVO

Fervo Energy CompanyUtilities

$17.07−$4.04

-19.1%

NASDAQ · Mkt cap $5.1 B

Fervo Energy dropped 19% on no identifiable news in the last 48 hours, suggesting the decline may reflect sector weakness, technical selling, or an untracked announcement or earnings release.

No headlines were available in the last 48 hours to explain Fervo's 19% single-day decline. Fervo Energy is a geothermal energy technology company, so possible catalysts for this magnitude of move could include disappointing project updates, revised guidance on commercialization timelines, changes in renewable energy policy tailwinds, or broader market rotation out of clean energy stocks. Without access to company filings, earnings releases, or confirmed news outside the provided feeds, it is impossible to pinpoint the specific trigger. The stock's position as the 45th biggest loser suggests this was a material, market-wide observation rather than isolated trading noise, but that alone does not reveal cause. Checking the company's IR page or SEC filings directly would be necessary to determine if an announcement was made outside Yahoo Finance's RSS coverage window.

ZNB

Color Star Technology Co., Ltd.Communication Services

$2.38−$0.56

-19.0%

NASDAQ · Mkt cap $448 K

No news headlines were found in the last 48 hours to explain ZNB's 19% drop, making it difficult to pinpoint a specific catalyst for the sharp decline.

Without any recent news headlines available, we cannot identify a confirmed catalyst for ZNB's significant 19% intraday loss. However, a 19% single-day drop in a micro-cap technology stock like Color Star Technology typically signals either a major negative development (earnings miss, dilutive financing, executive departure, or regulatory issue) that may not yet have surfaced in major news feeds, or a technical/liquidity-driven sell-off common in lower-volume stocks. Micro-cap stocks are particularly sensitive to momentum shifts, short covering reversals, or delayed disclosure of company-specific news. Without access to the company's investor relations channels or SEC filings from today, the specific trigger remains unidentified, though the magnitude suggests a material adverse event rather than routine market noise.

NVA.WT

$5.59−$1.31

-19.0%

CNCK

Coincheck Group N.V. Ordinary SharesFinancial Services

$1.88−$0.44

-19.0%

NASDAQ · Mkt cap $389 M

No financial news or announcements were found in the last 48 hours to explain the 18.97% drop in CNCK shares, leaving the trigger unclear and suggesting either delayed news disclosure, technical selling, or untracked market-moving events.

Coincheck Group N.V. experienced a sharp 18.97% decline on July 29, 2026, but no relevant headlines appeared in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect between a top-50 daily loser ranking and news absence is notable. For a cryptocurrency exchange or fintech-adjacent stock like CNCK, typical catalysts include regulatory actions against crypto platforms, exchange security incidents, guidance downgrades, or shifts in institutional appetite for crypto exposure. The absence of captured headlines could reflect delayed reporting, trading halts being disclosed later, announcements made through non-RSS channels, or simply that the market is reacting to something other than freshly released company information. Without additional context on the company's recent quarterly performance, regulatory status, or macro crypto sentiment shifts, we cannot pinpoint the specific driver.

AMBQ

Ambiq Micro, Inc.Technology

$57.29−$13.60

-18.9%

NYSE · Mkt cap $1.4 B

Ambiq Micro announced it will report Q2 2026 earnings results, triggering an 18.89% single-day drop likely due to disappointing guidance, missed expectations, or weak forward outlook disclosed in the announcement itself or accompanying materials.

The only headline in the past 48 hours is a July 28 announcement that Ambiq will report Q2 2026 financial results. This is a scheduled earnings report notice, not the actual results themselves. However, the magnitude of the stock's decline (down 18.89%, ranking 49th biggest loser) suggests that either the earnings announcement included guidance reduction, management commentary signaling weakness, or the market has already formed a negative consensus ahead of the full report. Without access to the full text of the July 28 announcement or any analyst downgrades issued simultaneously, we cannot determine whether the drop reflects actual disclosed results, pre-emptive negative guidance, or a broader sector/market sell-off affecting semiconductor and microelectronics firms. Earnings announcements typically drive large moves when they include forward-looking statements that disappoint investors.

ONTX

Onconova Therapeutics IncFinancial Services

$10.62−$2.43

-18.6%